365 related articles for article (PubMed ID: 31148598)
21. Resveratrol sensitizes glioblastoma-initiating cells to temozolomide by inducing cell apoptosis and promoting differentiation.
Li H; Liu Y; Jiao Y; Guo A; Xu X; Qu X; Wang S; Zhao J; Li Y; Cao Y
Oncol Rep; 2016 Jan; 35(1):343-51. PubMed ID: 26498391
[TBL] [Abstract][Full Text] [Related]
22. Biomimetic models to examine microenvironmental regulation of glioblastoma stem cells.
Nakod PS; Kim Y; Rao SS
Cancer Lett; 2018 Aug; 429():41-53. PubMed ID: 29746930
[TBL] [Abstract][Full Text] [Related]
23. miR-126-3p sensitizes glioblastoma cells to temozolomide by inactivating Wnt/β-catenin signaling via targeting SOX2.
Luo W; Yan D; Song Z; Zhu X; Liu X; Li X; Zhao S
Life Sci; 2019 Jun; 226():98-106. PubMed ID: 30980849
[TBL] [Abstract][Full Text] [Related]
24. Aspirin Affects Tumor Angiogenesis and Sensitizes Human Glioblastoma Endothelial Cells to Temozolomide, Bevacizumab, and Sunitinib, Impairing Vascular Endothelial Growth Factor-Related Signaling.
Navone SE; Guarnaccia L; Cordiglieri C; Crisà FM; Caroli M; Locatelli M; Schisano L; Rampini P; Miozzo M; La Verde N; Riboni L; Campanella R; Marfia G
World Neurosurg; 2018 Dec; 120():e380-e391. PubMed ID: 30144594
[TBL] [Abstract][Full Text] [Related]
25. Elevation of the TP53 isoform Δ133p53β in glioblastomas: an alternative to mutant p53 in promoting tumor development.
Kazantseva M; Eiholzer RA; Mehta S; Taha A; Bowie S; Roth I; Zhou J; Joruiz SM; Royds JA; Hung NA; Slatter TL; Braithwaite AW
J Pathol; 2018 Sep; 246(1):77-88. PubMed ID: 29888503
[TBL] [Abstract][Full Text] [Related]
26. Human cerebrospinal fluid affects chemoradiotherapy sensitivities in tumor cells from patients with glioblastoma.
Stringer BW; De Silva MI; Greenberg Z; Noreña Puerta A; Adams R; Milky B; Zabolocki M; van den Hurk M; Ebert LM; Fairly Bishop C; Conn SJ; Kichenadasse G; Michael MZ; Ormsby RJ; Poonoose S; Bardy C
Sci Adv; 2023 Oct; 9(43):eadf1332. PubMed ID: 37878712
[TBL] [Abstract][Full Text] [Related]
27. Isofuranodiene synergizes with temozolomide in inducing glioma cells death.
Brunetti A; Marinelli O; Morelli MB; Iannarelli R; Amantini C; Russotti D; Santoni G; Maggi F; Nabissi M
Phytomedicine; 2019 Jan; 52():51-59. PubMed ID: 30599912
[TBL] [Abstract][Full Text] [Related]
28. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas.
Brandsma D; Stalpers L; Taal W; Sminia P; van den Bent MJ
Lancet Oncol; 2008 May; 9(5):453-61. PubMed ID: 18452856
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of cyclin E1 overcomes temozolomide resistance in glioblastoma by Mcl-1 degradation.
Liang H; Chen Z; Sun L
Mol Carcinog; 2019 Aug; 58(8):1502-1511. PubMed ID: 31045274
[TBL] [Abstract][Full Text] [Related]
30. A 3D Bioprinted Human Neurovascular Unit Model of Glioblastoma Tumor Growth.
Tung YT; Chen YC; Derr K; Wilson K; Song MJ; Ferrer M
Adv Healthc Mater; 2024 Jun; 13(15):e2302831. PubMed ID: 38394389
[TBL] [Abstract][Full Text] [Related]
31. The HIF‑1α/miR‑224‑3p/ATG5 axis affects cell mobility and chemosensitivity by regulating hypoxia‑induced protective autophagy in glioblastoma and astrocytoma.
Huang S; Qi P; Zhang T; Li F; He X
Oncol Rep; 2019 Mar; 41(3):1759-1768. PubMed ID: 30569180
[TBL] [Abstract][Full Text] [Related]
32. Intertumoral heterogeneity in patient-specific drug sensitivities in treatment-naïve glioblastoma.
Skaga E; Kulesskiy E; Fayzullin A; Sandberg CJ; Potdar S; Kyttälä A; Langmoen IA; Laakso A; Gaál-Paavola E; Perola M; Wennerberg K; Vik-Mo EO
BMC Cancer; 2019 Jun; 19(1):628. PubMed ID: 31238897
[TBL] [Abstract][Full Text] [Related]
33. Tubastatin A, an inhibitor of HDAC6, enhances temozolomide‑induced apoptosis and reverses the malignant phenotype of glioblastoma cells.
Urdiciain A; Erausquin E; Meléndez B; Rey JA; Idoate MA; Castresana JS
Int J Oncol; 2019 May; 54(5):1797-1808. PubMed ID: 30864703
[TBL] [Abstract][Full Text] [Related]
34. Novel nanohydrogel of hyaluronic acid loaded with quercetin alone and in combination with temozolomide as new therapeutic tool, CD44 targeted based, of glioblastoma multiforme.
Barbarisi M; Iaffaioli RV; Armenia E; Schiavo L; De Sena G; Tafuto S; Barbarisi A; Quagliariello V
J Cell Physiol; 2018 Oct; 233(10):6550-6564. PubMed ID: 29030990
[TBL] [Abstract][Full Text] [Related]
35. Are There Thresholds in Glioblastoma Cell Death Responses Triggered by Temozolomide?
He Y; Kaina B
Int J Mol Sci; 2019 Mar; 20(7):. PubMed ID: 30925722
[TBL] [Abstract][Full Text] [Related]
36. Down-regulation of MDR1 by Ad-DKK3 via Akt/NFκB pathways augments the anti-tumor effect of temozolomide in glioblastoma cells and a murine xenograft model.
Fujihara T; Mizobuchi Y; Nakajima K; Kageji T; Matsuzaki K; Kitazato KT; Otsuka R; Hara K; Mure H; Okazaki T; Kuwayama K; Nagahiro S; Takagi Y
J Neurooncol; 2018 Sep; 139(2):323-332. PubMed ID: 29779087
[TBL] [Abstract][Full Text] [Related]
37. Metformin treatment reduces temozolomide resistance of glioblastoma cells.
Yang SH; Li S; Lu G; Xue H; Kim DH; Zhu JJ; Liu Y
Oncotarget; 2016 Nov; 7(48):78787-78803. PubMed ID: 27791206
[TBL] [Abstract][Full Text] [Related]
38. CD73 Downregulation Decreases In Vitro and In Vivo Glioblastoma Growth.
Azambuja JH; Gelsleichter NE; Beckenkamp LR; Iser IC; Fernandes MC; Figueiró F; Battastini AMO; Scholl JN; de Oliveira FH; Spanevello RM; Sévigny J; Wink MR; Stefani MA; Teixeira HF; Braganhol E
Mol Neurobiol; 2019 May; 56(5):3260-3279. PubMed ID: 30117104
[TBL] [Abstract][Full Text] [Related]
39. The TNF receptor family member Fn14 is highly expressed in recurrent glioblastoma and in GBM patient-derived xenografts with acquired temozolomide resistance.
Hersh DS; Harder BG; Roos A; Peng S; Heath JE; Legesse T; Kim AJ; Woodworth GF; Tran NL; Winkles JA
Neuro Oncol; 2018 Sep; 20(10):1321-1330. PubMed ID: 29897522
[TBL] [Abstract][Full Text] [Related]
40. Blocking distinct interactions between Glioblastoma cells and their tissue microenvironment: A novel multi-targeted therapeutic approach.
Mettang M; Meyer-Pannwitt V; Karpel-Massler G; Zhou S; Carragher NO; Föhr KJ; Baumann B; Nonnenmacher L; Enzenmüller S; Dahlhaus M; Siegelin MD; Stroh S; Mertens D; Fischer-Posovszky P; Schneider EM; Halatsch ME; Debatin KM; Westhoff MA
Sci Rep; 2018 Apr; 8(1):5527. PubMed ID: 29615749
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
